Kolitz J - Search Results

1

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.

Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. Berman E, et al. Among authors: kolitz j. Blood. 1991 Apr 15;77(8):1666-74. Blood. 1991. PMID: 2015395 Free article. Clinical Trial.

2

A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.

Kolitz JE, Kempin SJ, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gee T, Clarkson BD. Kolitz JE, et al. Semin Oncol. 1992 Jun;19(3 Suppl 9):27-33. Semin Oncol. 1992. PMID: 1641654

3

Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.

Crown JP, Gulati S, Straus DJ, Kolitz J, Heelan R, O'Brien J, Lee BJ, Portlock C, Bertino J. Crown JP, et al. Among authors: kolitz j. Invest New Drugs. 1991 May;9(2):185-6. doi: 10.1007/BF00175086. Invest New Drugs. 1991. PMID: 1874601 Clinical Trial.

4

Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.

Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW, et al. Berman E, et al. Among authors: kolitz j. Semin Oncol. 1989 Feb;16(1 Suppl 2):30-4. Semin Oncol. 1989. PMID: 2928808 Clinical Trial. No abstract available.

5

Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.

Shimazaki C, Atzpodien J, Wisniewski D, Gulati SC, Kolitz JE, Fried J, Clarkson BD. Shimazaki C, et al. Among authors: kolitz je. Acta Haematol. 1988;80(4):203-9. doi: 10.1159/000205638. Acta Haematol. 1988. PMID: 3146198

6

Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.

Atzpodien J, Gulati SC, Shimazaki C, Bührer C, Oz S, Kwon JH, Kolitz JE, Clarkson BD. Atzpodien J, et al. Among authors: kolitz je. Oncology. 1988;45(6):437-43. doi: 10.1159/000226661. Oncology. 1988. PMID: 3263598

7

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R. Chapman PB, et al. Among authors: kolitz je. Invest New Drugs. 1988 Sep;6(3):179-88. doi: 10.1007/BF00175395. Invest New Drugs. 1988. PMID: 3263958

8

Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivo.

Atzpodien J, Gulati SC, Kwon JH, Kushner BH, Shimazaki C, Bührer C, Oz S, Kolitz JE, Welte K, Clarkson BD. Atzpodien J, et al. Among authors: kolitz je. Exp Cell Biol. 1988;56(5):236-44. doi: 10.1159/000163486. Exp Cell Biol. 1988. PMID: 3265922

9

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, Godfrey S, Robert F, Schiffer CA. Moore JO, et al. Among authors: kolitz j. Blood. 1997 Feb 1;89(3):780-8. Blood. 1997. PMID: 9028308 Free article. Clinical Trial.

10

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.

Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Pinilla-Ibarz J, et al. Among authors: kolitz j. Blood. 2000 Mar 1;95(5):1781-7. Blood. 2000. PMID: 10688838 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters